LADA and CARDS: A prospective study of clinical outcome in established adult-onset autoimmune diabetes

Diabetes Care

Volumn 37, Issue 6, 2014, Pages 1643-1649

  Hawa, Mohammed Iqbal ^a   Buchan, Ana Paula ^a   Ola, Thomas ^a   Wun, Chuan Chuan ^b   DeMicco, David A ^b   Bao, Weihang ^b   Betteridge, D John ^c   Durrington, Paul N ^d   Fuller, John H ^c   Neil, H Andrew W ^e   Colhoun, Helen ^f   Leslie, Richard David ^a   Hitman, Graham A ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b PFIZER INC   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; AUTOANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; INSULINOMA ASSOCIATED ANTIGEN 2; PLACEBO; UNCLASSIFIED DRUG; ZINC TRANSPORTER 8; ANTIDIABETIC AGENT; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 1; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; INSULIN; PYRROLE DERIVATIVE;

ADULT; ADULT ONSET AUTOIMMUNE DIABETES; AGED; ARTICLE; AUTOIMMUNE DISEASE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PREVALENCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EPIDEMIOLOGY; GERMANY; GLUCOSE INTOLERANCE; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PHENOTYPE; RISK FACTOR;

ADULT; AGE OF ONSET; AGED; ANTICHOLESTEREMIC AGENTS; AUTOANTIBODIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GERMANY; GLUCOSE INTOLERANCE; GLUTAMATE DECARBOXYLASE; HEPTANOIC ACIDS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PHENOTYPE; PREVALENCE; PROSPECTIVE STUDIES; PYRROLES; RISK FACTORS;

EID: 84901421772     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2383     Document Type: Article

References (25)

1. Zinman B, Kahn SE, Haffner SM, O'Neill MC, Heise MA, Freed MI; ADOPT Study Group. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes 2004;53: 3193-3200
2. Rolandsson OPJ, Palmer JP. Latent autoimmunediabetes in adults (LADA) is dead: long live autoimmune diabetes! Diabetologia 2010; 53:1250-1253
3. Colhoun HM, Thomason MJ, Mackness MI, et al.; Collaborative AtoRvastatin Diabetes Study (CARDS). Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med 2002; 19:201-211
4. Colhoun HM, Betteridge DJ, Durrington PN, et al.; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatindiabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364: 685-696
5. Hawa MI, Thivolet C,Mauricio D, et al.; Action LADA Group. Metabolic syndrome and autoimmune diabetes: Action LADA 3. Diabetes Care 2009;32:160-164
6. Myhill P, Davis WA, Bruce DG, Mackay IR, Zimmet P, Davis TM. Chronic complications and mortality in community-based patients with latent autoimmune diabetes in adults: the Fremantle Diabetes Study. Diabet Med 2008;25:1245-1250
7. Roh MO, Jung CH, Kim BY, Mok JO, Kim CH. The prevalence and characteristics of latent autoimmunediabetes in adults (LADA) and its relation with chronic complications in a clinical department of a university hospital in Korea. Acta Diabetol 2013;50:129-134
8. Andersen CD, Bennet L, Nystrom L, et al. Worse glycaemic control in LADA patients than in those with type 2 diabetes, despite a longer time on insulin therapy. Diabetologia 2013;56:252-258
9. Isomaa B, Almgren P, Henricsson M, et al. Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA). Diabetes Care 1999;22:1347-1353
10. HawaMI, Fava D, Medici F, et al. Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality. Diabetes Care 2000;23:228-233
11. Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007;104:17040-17045
12. Torn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ; Participating Laboratories. Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008;51:846-852
13. Lampasona V, Schlosser M, Mueller PW, et al. Diabetes antibody standardization program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8. Clin Chem 2011;57:1693-1702
14. Alberti KG, Zimmet P, Shaw J. Metabolic syndromeda new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-480
15. Rasouli B, Grill V, Midthjell K, Ahlbom A, Andersson T, Carlsson S. Smoking is associated with reduced risk of autoimmune diabetes in adults contrasting with increased risk in overweight men with type 2 diabetes: a 22-year follow-up of the HUNT study. Diabetes Care 2013;36:604-610
16. Brophy S, Davies H, Mannan S, Brunt H, Williams R. Interventions for latent autoimmunediabetes (LADA) in adults. Cochrane Database Syst Rev. RE:view 2011
17. Hawa MI, Kolb H, Schloot N, et al.; Action LADA consortium. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care 2013;36:908-913
18. Turner R, Stratton I, Horton V, et al.; UK Prospective Diabetes Study Group. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 1997; 350:1288-1293
19. Buzzetti R, Di Pietro S, Giaccari A, et al.; Non Insulin Requiring Autoimmune Diabetes Study Group. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 2007;30: 932-938
20. Hossz ́ ufalusi N, Vatay A, Rajczy K, et al. Similar genetic features and different islet cell autoantibody pattern of latent autoimmunediabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression.diabetes Care 2003;26:452-457
21. Sørgjerd EP, Skorpen F, Kvaløy K, Midthjell K, Grill V. Time dynamics of autoantibodies are coupled to phenotypes and add to the heterogeneity of autoimmune diabetes in adults: the HUNT study, Norway. Diabetologia 2012;55: 1310-1318
22. Howson JM, Rosinger S, Smyth DJ, Boehm BO, Todd JA; ADBW-END Study Group. Genetic analysis of adult-onset autoimmune diabetes.diabetes 2011;60:2645-2653
23. Zhou Z, Xiang Y, Ji L, et al.; LADA China Study Group. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study.diabetes 2013;62:543-550
24. Lampasona V, Petrone A, Tiberti C, et al.; Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study Group. Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: Non Insulin Requiring Autoimmune Diabetes (NIRAD) 4. Diabetes Care 2010;33:104-108
25. Brophy S, Yderstraede K, Mauricio D, et al.; Action LADA Group. Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults. Diabetes Care 2008;31:439-441